Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method

Journal of Clinical Microbiology

Volumn 43, Issue 11, 2005, Pages 5685-5689

  Ou, Zhi Ying ^a   Liu, Na ^a   Chen, Chang Jie ^a   Cheng, Gang ^a   He, Yun Shao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ACCURACY; ARTICLE; DNA SEQUENCE; DOT HYBRIDIZATION; FLOW THROUGH HYBRIDIZATION; GENOTYPE; HEPATITIS B VIRUS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE DOT BLOT HYBRIDIZATION; SENSITIVITY AND SPECIFICITY; VIRUS GENOME; VIRUS MUTANT; VIRUS TYPING;

AMINO ACID MOTIFS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; NUCLEIC ACID HYBRIDIZATION; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 27744558896     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.11.5685-5689.2005     Document Type: Article

References (22)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, L. D. Condreay et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Allen, M. I., J. Gauthier, M. DesLauriers, E. J. Bourne, K. M. Carrick, F. Baldanti, L. L. Ross, M. W. Lutz, and L. D. Condreay. 1999. Two sensitive PCR-based methods for detection of hepatitis B variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 37:3338-3347.
3. Bai, Y. J., J. R. Zhao, G. T. Lv, W. H. Zhang, Y. Wang, and X. J. Yan. 2003. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J. Gastroenterol. 9:2344-2347.
4. Bartholmeusz, A., R. F. Schinazi, and S. A. Locarnini. 1998. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hep. Rev. 4:167-187.
5. Cane, P. A., P. Cook, D. Ratcliffe, D. Mutimer, and D. Pillay. 1999. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob. Agents Chemother. 43:1600-1608.
6. Chayama, K., Y. Suzuki, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
7. Clarke, B., and S. Bloor. 2002. Molecular genotyping of hepatitis B virus. J. Clin. Virol. 25:S41-S45.
8. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. Hann, Z. Goodman, L. Crowther, L. D. Condreay, M. Woessner, M. Rubin, and N. A. Brown. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
9. Engelke, D. R., P. A. Hoener, and F. S. Collins. 1988. Direct sequencing of enzymatically amplified human genomic DNA. Proc. Natl. Acad. Sci. USA 85:544-548.
10. Heo, J., M. Cho, H. H. Kim, Y. M. Shin, H. J. Jang, H. K. Park, C. M. Kim, G. H. Kim, D. H. Kang, G. A. Song, and U. S. Yang. 2004. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J. Korean Med. Sci. 19:541-546.
11. Hong, S. P., N. K. Kim, S. G. Hwang, H. J. Chung, S. Kim, J. H. Han, H. T. Kim, K. S. Rim, M. S. Kang, W. Yoo, and S. O. Kim. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 40:837-844.
12. Jardi, R., M. Buti, F. Rodriguez-Frias, M. Cotrina, X. Costa, C. Pascual, R. Esteban, and J. Guardia. 1999. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83:181-187.
13. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
14. Leung, N. W. Y., C. L. Lai, T. T. Chang, R. Guan, C. M. Lee, K. Y. Ng, S. G. Lim, P. C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, and R. N. Chien. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
15. Maynard, J. E. 1990. Hepatitis B: global importance and need for control. Vaccine 8(Suppl. 1):S18-S20.
16. Niesters, H. G. M., R. A. De Man, S. D. Pas, E. Fries, and A. D. M. E. Osterhaus. 2002. Identification of a new variant in the YMDD motif of the hepatitis B polymerase gene selected during lamivudine therapy. J. Med. Microbiol. 51:695-699.
17. Ohishi, W., and K. Chayama. 2003. Rare quasispecies in the YMDD motif of hepatitis B virus detected by polymerase chain reaction with peptide nucleic acid clamping. Intervirology 46:355-361.
18. Stuyver, L., C. Van Geyt, S. De Gendt, G. Van Reybroeck, F. Zoulim, G. Leroux-Roels, and R. Rossau. 2000. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38:702-707.
19. Whalley, S. A., D. Brown, C. G. Teo, G. M. Dusheiko, and N. A. Saunders. 2001. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J. Clin. Microbiol. 39:1456-1459.
20. Zhang, Y., M. Y. Coyne, S. G. Will, C. H. Levenson, and E. S. Kawasaki. 1991. Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides. Nucleic Acids Res. 19:3929-3933.
21. Zoulim, F. 2001. Detection of hepatitis B virus resistance to antivirals. J. Clin. Virol. 21:243-253.
22. Zoulim, F., and C. Trépo. 1998. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:151-168.